Parasympathomimetic (muscarinic agonist)

Salagen (pilocarpine)

An approved treatment for Sjögren's Syndrome.

FDA Approved (1994)by Advanz Pharma (Salagen); generics from multiple makers
Preclinical
Phase 1
Phase 2
Phase 3
Approved
1994
Drug facts

The same compound appears under different names depending on the context. Here is how to identify Pilocarpine wherever you encounter it, plus the key facts at a glance.

Generic name
Pilocarpine
Brand name
Salagen
Drug class
Parasympathomimetic (muscarinic agonist)
Manufacturer
Advanz Pharma (Salagen); generics from multiple makers
How it's taken
Taken as a 5 mg oral tablet, 3 to 4 times daily.

An oral medication that stimulates saliva and tear production by activating muscarinic receptors on exocrine glands. Pilocarpine treats the dryness symptoms of Sjögren's syndrome but does not modify the underlying autoimmune disease process.

Where Pilocarpine fits

One of 2 FDA-approved oral secretagogues for Sjögren's dry mouth symptoms (along with cevimeline). Treats symptoms only; does not modify the underlying autoimmune disease. Often used in combination with artificial tears, saliva substitutes, and dental care. Disease-modifying therapies like ianalumab are in development but not yet available.

How Pilocarpine works

Sjögren's syndrome destroys the salivary and tear glands through autoimmune inflammation, leaving patients with severe dryness of the mouth and eyes. While the glands are damaged, many patients still have some residual gland tissue that can be stimulated to produce moisture.

Pilocarpine activates muscarinic receptors (specifically M3 receptors) on the remaining glandular cells, telling them to secrete saliva and tears. It essentially turns up the output of whatever gland tissue remains functional. This can significantly improve mouth moisture, reduce dental decay risk, and ease the difficulty swallowing and speaking that plagues many Sjögren's patients.

Pilocarpine is purely symptomatic: it helps manage dryness but does not slow the autoimmune attack on the glands. The effect lasts only while the drug is being taken, and it works best in patients who still have some residual gland function.

Mechanism: Muscarinic receptor agonist that stimulates exocrine glands (salivary, lacrimal, and sweat glands) to increase secretion of saliva and tears

Side effects and safety

What patients report

The most common side effect is sweating (affecting up to 40% of patients), which occurs because pilocarpine stimulates sweat glands along with salivary and tear glands. Other common effects include nausea, chills, flushing, increased urinary frequency, dizziness, and watery eyes. Most side effects are dose-related and can be managed by starting at a lower dose and gradually increasing. Pilocarpine should not be used in patients with uncontrolled asthma or narrow-angle glaucoma. The label also warns about use in people with significant heart disease or with controlled asthma, chronic bronchitis or COPD, and about blurred vision that can make night driving unsafe; it should be used with caution by people with gallbladder disease or kidney stones.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Pilocarpine

Taken as a 5 mg oral tablet, 3 to 4 times daily. The dose may be adjusted based on response and tolerability. Effects typically begin within 30 minutes and last 3-5 hours. Should be taken with a full glass of water.

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Help paying for Salagen

Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.

Your insurance
From the drugmaker
Salagen (Pilocarpine)

No drugmaker assistance program for this medicine is published on the maker's official pages.

Good to know: Pilocarpine tablets are sold as generics by many manufacturers; there is no single drugmaker assistance program. Ask your pharmacist about lower-cost generic options.

Checked on the drugmaker's official pages on September 24, 2026. Programs change; confirm with the program before you rely on it.

More ways to get help paying for treatment →

Clinical trial results

Multiple placebo-controlled trials in the 1990s demonstrated that pilocarpine significantly increased salivary flow rate and improved patient-reported dryness symptoms compared to placebo. These trials supported FDA approval for both radiation-induced dry mouth (1994) and Sjögren's syndrome dry mouth symptoms.

Development history

Pilocarpine has been used in medicine since the 19th century, originally as an eye drop for glaucoma. The oral formulation was developed for xerostomia (dry mouth) and received FDA approval for radiation-induced dry mouth in 1994 and for Sjögren's syndrome dry mouth in 1998. It remains one of only 2 FDA-approved oral secretagogues for Sjögren's dry mouth (alongside cevimeline).

Ask anything about Pilocarpine
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Tap to start:
Or start with one of these

Explore Sjögren's Syndrome trials

Other Sjögren's Syndrome treatments

Common questions about Pilocarpine

▸What is Pilocarpine (Salagen)?

An oral medication that stimulates saliva and tear production by activating muscarinic receptors on exocrine glands. Pilocarpine treats the dryness symptoms of Sjögren's syndrome but does not modify the underlying autoimmune disease process.

▸How does Pilocarpine work?

Sjögren's syndrome destroys the salivary and tear glands through autoimmune inflammation, leaving patients with severe dryness of the mouth and eyes. While the glands are damaged, many patients still have some residual gland tissue that can be stimulated to produce moisture.

Pilocarpine activates muscarinic receptors (specifically M3 receptors) on the remaining glandular cells, telling them to secrete saliva and tears. It essentially turns up the output of whatever gland tissue remains functional. This can significantly improve mouth moisture, reduce dental decay risk, and ease the difficulty swallowing and speaking that plagues many Sjögren's patients.

Pilocarpine is purely symptomatic: it helps manage dryness but does not slow the autoimmune attack on the glands. The effect lasts only while the drug is being taken, and it works best in patients who still have some residual gland function.

▸What are the side effects of Pilocarpine?

The most common side effect is sweating (affecting up to 40% of patients), which occurs because pilocarpine stimulates sweat glands along with salivary and tear glands. Other common effects include nausea, chills, flushing, increased urinary frequency, dizziness, and watery eyes. Most side effects are dose-related and can be managed by starting at a lower dose and gradually increasing. Pilocarpine should not be used in patients with uncontrolled asthma or narrow-angle glaucoma. The label also warns about use in people with significant heart disease or with controlled asthma, chronic bronchitis or COPD, and about blurred vision that can make night driving unsafe; it should be used with caution by people with gallbladder disease or kidney stones.

▸How is Pilocarpine taken?

Taken as a 5 mg oral tablet, 3 to 4 times daily. The dose may be adjusted based on response and tolerability. Effects typically begin within 30 minutes and last 3-5 hours. Should be taken with a full glass of water.

▸Is Pilocarpine FDA approved?

Yes, Pilocarpine (Salagen) is FDA approved (1994) for the treatment of Sjögren's Syndrome.

▸Does pilocarpine help with Sjogrens dry mouth?

Yes. Pilocarpine (Salagen) is FDA-approved for dry mouth symptoms in Sjogren's syndrome. It stimulates remaining salivary gland tissue to produce more saliva. It treats symptoms but does not slow the underlying autoimmune disease.

▸What is the most common side effect of pilocarpine?

Sweating is the most common side effect, affecting up to 40% of patients. This occurs because pilocarpine stimulates sweat glands along with salivary glands. Starting at a lower dose and gradually increasing can help manage this.

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. U.S. Food and Drug Administration. SALAGEN (pilocarpine HCl) Tablets Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237se8-004_salagen_lbl.pdf
  2. Archives of Internal Medicine. Pilocarpine for Xerostomia in Sjögren's Syndrome. https://pubmed.ncbi.nlm.nih.gov/9596072/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: September 2026.

Follow Pilocarpine (Salagen) news by email

One email when Pilocarpine (Salagen) has trial changes, FDA news, or label updates for its condition. No newsletter, no spam.

We never share your email. Unsubscribe anytime.